Publications by authors named "M P Crump"
Article Synopsis
- Brentuximab vedotin has been shown to improve outcomes in treating advanced classic Hodgkin's lymphoma, but it also causes more toxic side effects in adults, while many pediatric patients still need radiation therapy and face challenges with relapse.
- A phase 3 trial involving patients aged 12 and older tested two treatment combinations: brentuximab vedotin with standard chemotherapy (BV+AVD) versus nivolumab with standard chemotherapy (N+AVD), aiming to assess progression-free survival.
- Results indicated that N+AVD significantly enhances progression-free survival compared to BV+AVD, with a 2-year survival rate of 92% for N+AVD versus 83% for BV
Article Synopsis
- Some patients with a type of cancer called mantle cell lymphoma (MCL) don't have good treatment options if their cancer comes back.
- A study tested a new medicine called glofitamab, which was given after patients received another medicine to help reduce side effects.
- The results showed that many patients got better from the treatment, and while some had side effects, these were manageable with proper care.
The leinamycin family of polyketides are promising antitumor antibiotics, yet several aspects of their biosynthesis remain elusive. All leinamycin family members bear a sulfur-containing moiety which is essential for the anticancer activity exhibited by leinamycin. The key building blocks required for the incorporation of these functionalities are introduced in the final module of the polyketide synthase (PKS), which elegantly combines β-branching and thiocysteine incorporation to generate a diverse library of sulfur-based molecular scaffolds.
View Article and Find Full Text PDFIn the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.
View Article and Find Full Text PDFRadiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes.
View Article and Find Full Text PDF